RECRUITING

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Official Title

Phase I Trial of Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Quick Facts

Study Start:2023-10-25

Study Completion:2026-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06080061

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy * ECOG performance status of 0-2 * Age \> 18 years old * Ability to understand and the willingness to personally sign the written IRB approved informed consent document * Estimated life expectancy of 12 weeks or longer	* Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist * Age \< 18 years old * Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree * Diagnosis of interstitial pulmonary fibrosis * Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields

Inclusion Criteria

Exclusion Criteria

* Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
* ECOG performance status of 0-2
* Age \> 18 years old
* Ability to understand and the willingness to personally sign the written IRB approved informed consent document
* Estimated life expectancy of 12 weeks or longer

* Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
* Age \< 18 years old
* Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree
* Diagnosis of interstitial pulmonary fibrosis
* Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields

Contacts and Locations

Study Contact

Jillian Skerchak

CONTACT

650-721-4072

jskerch1@stanford.edu

Kelly Huang

CONTACT

650-724-4606

kelhuang@stanford.edu

Principal Investigator

Lucas K Vitzthum, MD

PRINCIPAL_INVESTIGATOR

Stanford University

Study Locations (Sites)

Stanford University

Palo Alto, California, 94305

United States

Collaborators and Investigators

Sponsor: Stanford University

Lucas K Vitzthum, MD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-25

Study Completion Date2026-12

Study Record Updates

Study Start Date2023-10-25

Study Completion Date2026-12

Terms related to this study

Additional Relevant MeSH Terms

Lung Cancer